CHRISTINA HARTMAN — Lobbyist Profile | Poliscope

CHRISTINA HARTMAN

Filings

Clients

Firms

Years active

2024–2026

Associated filing income

—

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
ORCHARD THERAPEUTICS NORTH AMERICA	13	2024–2026

Lobbying firms

Firm	Filings	Years
ORCHARD THERAPEUTICS NORTH AMERICA	13	2024–2026

Bills explicitly cited in this lobbyist’s assigned issues (36)

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

H.R. 10571

Surge to Save Newborns Act

Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text

FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including Appropriations and Accelerating Implementation and Providing Resources for States to Implement for Metachromatic Leukodystrophy (MLD) H.R. 10571: Surge to Save Newborns Act

H.R. 7871

MVP Act

Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text

S.1637/H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act CMS Policies to Support Expedited Implementation of Accelerating Kids' Access to Care Act (AKATCA) and States' Awareness of VBAs

Original LDA source filings (13)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

ORCHARD THERAPEUTICS NORTH AMERICA via ORCHARD THERAPEUTICS NORTH AMERICA

2026 · third_quarter · Q3

Firm income: —Client expense: $240,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

S.1637/H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act CMS Policies to Support Expedited Implementation of Accelerating Kids' Access to Care Act (AKATCA) and States' Awareness of VBAs

HCR

Health Issues

FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including Appropriations and Accelerating Implementation and Providing Resources for States to Implement for Metachromatic Leukodystrophy (MLD) H.R. 10571: Surge to Save Newborns Act

Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Source: Senate LDA

Show 9 more original filings

ORCHARD THERAPEUTICS NORTH AMERICA via ORCHARD THERAPEUTICS NORTH AMERICA

2025 · second_quarter · 2A

Firm income: —Client expense: $430,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Appropriations for Newborn Screening HR 1262/ S 932 - Give Kids a Chance Act of 2025

MMM

Medicare/Medicaid

Medicaid Value-Based Payments for Patients (MVP) Act HR 1509/ S 752 - Accelerating Kids' Access to Care Act & Give Kids a Chance Act 2025

Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

ORCHARD THERAPEUTICS NORTH AMERICA via ORCHARD THERAPEUTICS NORTH AMERICA

2025 · fourth_quarter · Q4

Firm income: —Client expense: $260,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

HR 1262/ S 932 - Give Kids a Chance Act of 2025 HR 1509/ S 752 - Accelerating Kids' Access to Care Act & Give Kids a Chance Act 2025 Newborn Screening, including Appropriations

MMM

Medicare/Medicaid

Medicaid Value-Based Payments for Patients (MVP) Act

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

ORCHARD THERAPEUTICS NORTH AMERICA via ORCHARD THERAPEUTICS NORTH AMERICA

2025 · third_quarter · Q3

Firm income: —Client expense: $220,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Appropriations for Newborn Screening HR 1262/ S 932 - Give Kids a Chance Act of 2025

MMM

Medicare/Medicaid

Medicaid Value-Based Payments for Patients (MVP) Act HR 1509/ S 752 - Accelerating Kids' Access to Care Act & Give Kids a Chance Act 2025

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

ORCHARD THERAPEUTICS NORTH AMERICA via ORCHARD THERAPEUTICS NORTH AMERICA

2025 · third_quarter · RA

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Matters affecting Medicare/Medicaid Issues

MMM

Medicare/Medicaid

Matters affecting Medicare/Medicaid Issues

PHA

Pharmacy

Matters affecting Medicare/Medicaid Issues

ORCHARD THERAPEUTICS NORTH AMERICA via ORCHARD THERAPEUTICS NORTH AMERICA

2025 · second_quarter · Q2

Firm income: —Client expense: $220,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Appropriations for Newborn Screening HR 1262/ S 932 - Give Kids a Chance Act of 2025

MMM

Medicare/Medicaid

Medicaid Value-Based Payments for Patients (MVP) Act HR 1509/ S 752 - Accelerating Kids' Access to Care Act & Give Kids a Chance Act 2025

Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

ORCHARD THERAPEUTICS NORTH AMERICA via ORCHARD THERAPEUTICS NORTH AMERICA

2025 · first_quarter · Q1

Firm income: —Client expense: $270,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Appropriations for Newborn Screening HR 1262/ S 932 - Give Kids a Chance Act of 2025

MMM

Medicare/Medicaid

HR 2666/S 4204 - Medicaid Value-Based Payments for Patients (MVP) Act S 891 - Inclusion of Accelerating Kids' Access to Care Act & Give Kids a Chance Act 2025

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ORCHARD THERAPEUTICS NORTH AMERICA via ORCHARD THERAPEUTICS NORTH AMERICA

2024 · fourth_quarter · Q4

Firm income: —Client expense: $130,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

S 4584 - Creating Hope Reauthorization Act of 2024

MMM

Medicare/Medicaid

HR 2666/S 4204 - Medicaid Value-Based Payments for Patients (MVP) Act HR 4758/S 2372 - Accelerating Kids' Access to Care Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ORCHARD THERAPEUTICS NORTH AMERICA via ORCHARD THERAPEUTICS NORTH AMERICA

2024 · third_quarter · Q3

Firm income: —Client expense: $60,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

HR 2666 - Medicaid Value-Based Payments for Patients (MVP) Act S 4204 - Medicaid Value-Based Payments for Patients (MVP) Act HR 4758 - Accelerating Kids' Access to Care Act Medicaid Program: Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program (CMS-2434-P)

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office

ORCHARD THERAPEUTICS NORTH AMERICA via ORCHARD THERAPEUTICS NORTH AMERICA

2024 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Matters affecting Medicare/Medicaid Issues

HCR

Health Issues

Matters affecting Medicare/Medicaid Issues

PHA

Pharmacy

Matters affecting Medicare/Medicaid Issues